LION bioscience Announces GlaxoSmithKline License Expansion
LION bioscience has announced that GlaxoSmithKline (GSK) has renewed its license for SRS and SRS Objects. With these renewals, which were received by the company in third quarter of fiscal year 2003/2004, GSK has expanded its collaboration with LION and has the license to use the LION technology globally. Financial details were not disclosed.
SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life science data – genetic, protein, cellular, molecular and clinical – from public and proprietary sources, regardless of data format. SRS is used in more than 300 commercial and academic sites delivering genomic data daily to thousands of users around the globe. SRS is the clear market leader for bioinformatics data integration, providing global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson&Johnson and AstraZeneca, as well as forming the basis of genomics portals for leading data providers such as Celera, Incyte, Derwent and Affymetrix.
“We are pleased that SRS continues to be the standard integration technology for biological data. With the release of SRS 8.0 this summer, we believe that this leading position will be further expanded,” said Dr. Daniel Keesman, co-CEO and Chief Operating Officer at LION.
http://www.lionbioscience.com/
